Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Columbus, Ohio

This page shows live ClinicalTrials.gov search results for Columbus, Ohio, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 5:46 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
10851
Shown on this page
12
Current sort
Recently updated
Location scope
Columbus, OH
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Columbus, Ohio. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 337–348 of 10,851 matching trials in Columbus, OH.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in Columbus

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Studying Different Ways of Using Oral Nicotine Pouches to Understand the Effect on Nicotine Delivery, Appeal, and Side Effects Among Adult Cigarette Smokers

NCT07899827
View directory record Official record
Conditions
Cigarette Smoking-Related Carcinoma
Interventions
Biospecimen Collection, Oral nicotine pouches, Survey Administration
Procedure · Drug · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
21 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 4, 2026, 5:46 PM EST
Recruiting Phase 1Phase 2 Interventional

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

NCT06564038
View directory record Official record
Conditions
Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma, B-cell Non-Hodgkin Lymphoma
Interventions
Surovatamig, Prednisone (or equivalent), Rituximab, Cyclophosphamide, Vincristine, Doxorubicin, Acalabrutinib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
13
States / cities
Boston, Massachusetts • Hackensack, New Jersey • New Brunswick, New Jersey + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 4, 2026, 5:46 PM EST
Completed Phase 2 Interventional Results available

Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

NCT02396134
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Hodgkin Lymphoma, Adult Non-Hodgkin Lymphoma, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Cytomegaloviral Infection, Hematopoietic and Lymphoid Cell Neoplasm, HLA-A*0201 Positive Cells Present, Myelodysplastic Syndrome, Adult Lymphoblastic Lymphoma, Chronic Lymphocytic Leukemia, Myelofibrosis, Myeloproliferative Neoplasm
Interventions
CMVpp65-A*0201 peptide vaccine, Placebo, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
5
States / cities
Duarte, California • Atlanta, Georgia • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 4, 2026, 5:46 PM EST
Recruiting Phase 3 Interventional

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

NCT06357533
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Datopotamab Deruxtecan, Rilvegostomig, Pembrolizumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
675 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
62
States / cities
Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 53 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 4, 2026, 5:46 PM EST
Recruiting Phase 2 Interventional

A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma

NCT07428616
View directory record Official record
Conditions
Meningioma
Interventions
Zanzalintinib
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
20
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 4, 2026, 5:46 PM EST
Recruiting Phase 1Phase 2 Interventional

Lead-212 PSV359 Therapy for Patients With Solid Tumors

NCT06710756
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Esophageal Cancer, Colorectal Cancer, Ovarian Cancer, Head and Neck Cancer, Sarcoma, Mesothelioma
Interventions
[203Pb]Pb-PSV359, [212Pb]Pb-PSV359
Drug
Lead sponsor
Perspective Therapeutics
Industry
Eligibility
18 Years to 90 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
16
States / cities
Los Angeles, California • Miami, Florida • Kansas City, Kansas + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 4, 2026, 5:46 PM EST
Recruiting Not applicable Interventional

Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy

NCT04565795
View directory record Official record
Conditions
Ureteral Diseases
Interventions
Uriprene® Degradable Temporary Ureteral Stent
Device
Lead sponsor
Adva-Tec
Industry
Eligibility
21 Years to 80 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Phoenix, Arizona • Los Angeles, California • Gainesville, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 4, 2026, 5:46 PM EST
Recruiting Phase 2 Interventional

CMV CTLs in Neonates With CMV Infection

NCT05564598
View directory record Official record
Conditions
Congenital Cytomegaloviral (CMV) Disease
Interventions
CMV Cytotoxic T-Lymphocytes, Anti-viral Therapy
Biological · Drug
Lead sponsor
New York Medical College
Other
Eligibility
0 Days to 21 Days
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
4
States / cities
Los Angeles, California • St Louis, Missouri • Vallhala, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 4, 2026, 5:46 PM EST
Recruiting Not applicable Interventional

Trial of Ureteroscopy vs Steerable Continuous Flow Aspiration Technology

NCT07101809
View directory record Official record
Conditions
Urolithiasis, Stones, Kidney, Renal Stones, Kidney Stones
Interventions
Steerable Ureteroscopic Renal Evacuation (SURE) using the CVAC System, Standard Ureteroscopy (URS)
Device
Lead sponsor
Calyxo, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
6
States / cities
Birmingham, Alabama • Gainesville, Florida • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 4, 2026, 5:46 PM EST
Active, not recruiting Phase 3 Interventional

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis

NCT05269004
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ocrelizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
48
States / cities
Phoenix, Arizona • Laguna Hills, California • Palo Alto, California + 39 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 4, 2026, 5:46 PM EST
Recruiting Phase 2 Interventional

To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment

NCT07684820
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
EXPD-101/FXS7553 Dose 1, EXPD-101/FXS7553 Dose 2, Placebo
Drug
Lead sponsor
Expedition Therapeutics, Inc
Industry
Eligibility
40 Years to 85 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
29
States / cities
Phoenix, Arizona • Encino, California • Northridge, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 4, 2026, 5:46 PM EST
Recruiting Phase 3 Interventional

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

NCT03418961
View directory record Official record
Conditions
Cardiotoxicity, HER2/Neu Positive, Metastatic Malignant Neoplasm in the Brain, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Carvedilol, Laboratory Biomarker Analysis, Patient Observation
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
491 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2031
U.S. locations
577
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Hot Springs, Arkansas + 375 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 4, 2026, 5:46 PM EST